Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Summary The purpose of this study is to assess BMS-986453 in participants with relapse d and/or refractory multiple myeloma (RRMM).
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease. Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry. Participants in Part A and Part B Cohort 1 must have received at least 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Participants must have adequate organ function. Exclusion Criteria: Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma. Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis. Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis. Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
University of Alabama at Birmingham Birmingham Alabama, 35294, United States
More Info
Local Institution - 0003 Duarte California, 91010, United States
More Info
Local Institution - 0011 San Francisco California, 94143, United States
More Info
Local Institution - 0006 Stanford California, 94305, United States
More Info
Colorado Blood Cancer Institute Denver Colorado, 80218, United States
More Info
Local Institution - 0005 New Haven Connecticut, 06510, United States
More Info
Local Institution - 0016 Tampa Florida, 33612, United States
More Info
Icahn School of Medicine at Mount Sinai New York New York, 10029, United States
More Info
Memorial Sloan Kettering Cancer Center New York New York, 10065, United States
More Info
Local Institution - 0008 Nashville Tennessee, 37203, United States
More Info
Local Institution - 0020 Nashville Tennessee, 37203, United States
More Info
Swedish Medical Center Seattle Washington, 98104, United States
More Info
Local Institution - 0019 Paris , 75010, France
More Info
Local Institution - 0021 Heidelberg , D-691, Germany
More Info
Local Institution - 0017 Köln , 50937, Germany
More Info
Local Institution - 0018 Wuerzburg , 97080, Germany
More Info
Local Institution - 0015 Pamplona Navarra, 31008, Spain
More Info
Local Institution - 0014 Salamanca , 37007, Spain
More Info How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up